Gongwin Biopharm Holdings Co., Ltd. (TPEX: 6617)

Gongwin Biopharm Holdings Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,589	273.59	671.51	454.12	707.23	189.7
Short-Term Investments	289.57	668.66	434.1	372.2	297.09	423.2
Trading Asset Securities	-	-	-	-	34.41	33.17
Cash & Short-Term Investments	2,879	942.25	1,106	826.33	1,039	646.07
Cash Growth	180.03%	-14.78%	33.80%	-20.45%	60.78%	-14.19%
Accounts Receivable	9.06	10.58	-	-	-	-
Other Receivables	9.04	4.52	4.25	0.06	0.21	0.28
Receivables	18.1	15.1	4.25	0.06	0.21	0.28
Inventory	12.28	11.93	0.21	-	-	-
Prepaid Expenses	13.69	11.36	11.11	-	-	-
Other Current Assets	146.28	138.42	215.88	93.74	21.34	9.82
Total Current Assets	3,069	1,119	1,337	920.12	1,060	656.17
Property, Plant & Equipment	313.1	118.32	245.05	246.76	136.97	111.4
Long-Term Investments	191.61	156.61	32.35	3.88	5.34	5.62
Other Intangible Assets	0.25	0.19	-	-	0.01	0.11
Other Long-Term Assets	119.99	121.17	7.47	1.12	1.42	1.42
Total Assets	3,694	1,515	1,622	1,172	1,204	774.72
Accounts Payable	0.13	0.29	-	-	-	-
Accrued Expenses	34.11	26.37	32.63	21.97	19.03	18.97
Short-Term Debt	241.55	75.02	134.55	113.06	29.28	20.73
Current Portion of Leases	0.04	2.12	5.01	1.99	4.7	2.85
Current Income Taxes Payable	15.62	15.13	15.44	15.2	-	-
Other Current Liabilities	7.25	7.44	3.62	2.54	2.66	5.66
Total Current Liabilities	298.69	126.36	191.26	154.75	55.66	48.2
Long-Term Leases	0.01	0.03	2.18	0.1	2.11	-
Long-Term Unearned Revenue	45.43	45.08	42.03	29.57	27.97	29.93
Other Long-Term Liabilities	41.44	32.06	13.24	0	-	-
Total Liabilities	385.58	203.53	248.7	184.43	85.75	78.13
Common Stock	1,275	1,133	1,131	1,099	1,093	1,031
Additional Paid-In Capital	3,501	1,644	1,634	1,061	1,045	556.41
Retained Earnings	-1,492	-1,441	-1,349	-1,094	-972.88	-879.81
Comprensive Income & Other	30.42	-21.35	-24.77	-95.34	-71.36	-42.06
Total Common Equity	3,315	1,315	1,392	970.72	1,093	665.57
Minority Interest	-6.32	-3.68	-18.58	16.74	25.21	31.02
Shareholders' Equity	3,309	1,312	1,373	987.45	1,118	696.59
Total Liabilities & Equity	3,694	1,515	1,622	1,172	1,204	774.72
Total Debt	241.6	77.17	141.74	115.14	36.09	23.58
Net Cash (Debt)	2,637	865.08	963.87	711.19	1,003	622.49
Net Cash Growth	200.65%	-10.25%	35.53%	-29.07%	61.07%	-4.85%
Net Cash Per Share	23.16	7.64	8.67	6.49	9.60	6.04
Filing Date Shares Outstanding	127.51	113.34	113.09	109.92	109.27	103.1
Total Common Shares Outstanding	127.51	113.34	113.09	109.92	109.27	103.1
Working Capital	2,770	992.7	1,146	765.37	1,005	607.97
Book Value Per Share	26.00	11.61	12.31	8.83	10.00	6.46
Tangible Book Value	3,315	1,315	1,392	970.72	1,093	665.46
Tangible Book Value Per Share	26.00	11.61	12.31	8.83	10.00	6.45
Land	228.65	49.69	155	155	49.69	49.69
Buildings	71.39	52.95	69.59	69.23	53.22	35.61
Machinery	67.28	63.43	56.76	54.91	54.13	37.24
Construction In Progress	-	-	-	0.54	-	5.77
Leasehold Improvements	3.75	3.75	3.75	3.75	3.75	3.75

Source: S&P Capital IQ. Standard template. Financial Sources.